Page last updated: 2024-12-10

2-(allylthio)pyrazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-(allylthio)pyrazine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3025899
SCHEMBL ID4156992
MeSH IDM0273913

Synonyms (8)

Synonym
2-(allylthio)pyrazine
2-prop-2-enylsulfanylpyrazine
164352-89-0
ZYBMMXTUPCNGBL-UHFFFAOYSA-N
2 -(2-propenylthio)pyrazine
2-(2-propenylthio)pyrazine
SCHEMBL4156992
DTXSID00167748

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" After intravenous administration of 2-AP, 10, 20, and 50 mg/kg, to rabbits, the pharmacokinetic parameters of 2-AP, such as the total area under the plasma concentration-time curve from time 0 to 12 h (261, 672, and 1190 micrograms min/ml), the total body clearance (38."( Pharmacokinetics of a chemoprotective agent, 2-(allylthio)pyrazine, after intravenous administration to rabbits.
Han, KS; Koo, CH; Lee, MG; Woo, SJ, 1998
)
0.56
" administration, the pharmacokinetic parameters of 2-AP were dose-independent at the dose ranges studied."( Pharmacokinetics of a chemoprotective agent, 2-(allylthio)pyrazine, after intravenous and oral administration to rats: hepatic and gastric first-pass effects.
Han, KS; Lee, MG, 1999
)
0.56
" In rats with PCMC, some pharmacokinetic parameters of 2-AP restored fully or more than the levels of control rats."( Effects of cysteine on the pharmacokinetics of intravenous 2-(allylthio)pyrazine, a new chemoprotective agent, in rats with protein-calorie malnutrition.
Cho, MK; Kim, DH; Kim, SG; Kwon, JW; Lee, MG; Yim, YG, 2003
)
0.56

Bioavailability

ExcerptReferenceRelevance
" The extent of absolute oral bioavailability (F) values also increased with increasing oral doses; the values were 19."( Pharmacokinetics of a chemoprotective agent, 2-(allylthio)pyrazine, after intravenous and oral administration to rats: hepatic and gastric first-pass effects.
Han, KS; Lee, MG, 1999
)
0.56

Dosage Studied

ExcerptRelevanceReference
" Thus, the lipid emulsion with soybean oil and lecithin could be used as a potential dosage form with the liver-targeting property and enhanced stability of sparingly water-soluble 2-AP."( Preparation and evaluation of 2-(allylthio)pyrazine-loaded lipid emulsion with enhanced stability and liver targeting.
Choi, HG; Jang, JH; Kim, CK; Sung, JH, 2009
)
0.64
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's18 (69.23)18.2507
2000's8 (30.77)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.89

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.89 (24.57)
Research Supply Index3.33 (2.92)
Research Growth Index4.22 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.89)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.70%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (96.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]